Cardiac device infections occurred in 3.4% of patients at 12 months post-ICD implant and resulted in a mean 3-year incremental expenditure of €31,493 to €33,777 compared with matched controls.
Case-Control
What is the incidence and incremental cost of cardiac device infections in patients with implantable cardioverter defibrillators?
Cardiac device infections following ICD implantation occur in 3.4% of patients at 12 months and are associated with substantial incremental healthcare costs exceeding €30,000 over 3 years.
AIM: Estimate incidence and costs of cardiac device infections (CDIs) in Germany. MATERIALS & METHODS: Patients had an implantable cardioverter defibrillator implanted over 2010-2013 and were followed to December 2014 using German health insurance claims data. A case-controlled analysis was performed using propensity score matching methods. RESULTS: Risk of CDI 12 months post-implant was 3.4% overall, either 2.9% for de novo procedures versus 4.4% for replacement procedures. Mean 3-year incremental expenditure per patient for patients with CDI compared with controls was €31,493 for de novo implant patients and €33,777 for replacement patients. Mean incremental expenditure was €59,419 per patient with a major infection. CONCLUSION: CDIs are highly expensive to manage, reinforcing the need for strategies to reduce their occurrence.
Ludwig et al. (Tue,) conducted a case-control in Implantable cardioverter defibrillator implantation. Cardiac device infection (CDI) vs. Matched controls without CDI was evaluated on Incidence of CDI at 12 months post-implant. Cardiac device infections occurred in 3.4% of patients at 12 months post-ICD implant and resulted in a mean 3-year incremental expenditure of €31,493 to €33,777 compared with matched controls.